RMC-6272
Modify Date: 2025-12-01 18:00:24
RMC-6272 structure
|
Common Name | RMC-6272 | ||
|---|---|---|---|---|
| CAS Number | 2382769-46-0 | Molecular Weight | 1850.22 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C95H141FN6O27S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RMC-6272RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors[1]. |
| Name | RMC-6272 |
|---|
| Description | RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors[1]. |
|---|---|
| Related Catalog | |
| In Vitro | RMC-6272 shows more effective growth inhibition in multiple TSC1 or TSC2 mutant tumor cell lines compared to Rapamycin. RMC-6272 causes a more profound growth inhibition in the TSC1 or TSC2 mutant cells than the wild type cells. RMC-6272 at ~1 nM shows near complete inhibition of p4E-BP1T37/46, while inhibition of pS6S240/244 levels is similar for Rapamycin and RM compounds[1]. |
| In Vivo | RMC-6272 markedly reduces kidney tumor burden in Tsc2+/- A/J mice after four weeks of treatment. Tumor regrowth is assessed two months after treatment cessation, tumor burden is significantly reduced in the RMC-6272 group as compared to the Rapamycin and MLN0128 groups[1]. |
| References |
| Molecular Formula | C95H141FN6O27S |
|---|---|
| Molecular Weight | 1850.22 |
| InChIKey | SBCMKKFTXRBACH-URWOFZDBSA-N |
| SMILES | COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCS(=O)(=O)c3ccc(C(=O)N4CCOc5ccc(-c6ccc(N)nc6)cc5C4)c(C)c3F)C(OC)C2)CC(O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C |